Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Sep 12;11(2):e001210.
doi: 10.1136/lupus-2024-001210.

Hospitalised infections and rituximab administration among children and adolescents with systemic lupus erythematosus from 2009 to 2021

Jordan E Roberts  1   2 , Anna V Faino  3 , Mersine A Bryan  4   2 , Jonathan D Cogen  2   5 , Esi M Morgan  4   2
Affiliations

Hospitalised infections and rituximab administration among children and adolescents with systemic lupus erythematosus from 2009 to 2021

Jordan E Roberts et al. Lupus Sci Med. .

Abstract

Background: Rituximab is associated with high infection rates, but studies of infections following rituximab in youth with childhood-onset SLE (cSLE) are limited. We conducted a retrospective longitudinal cohort study to assess the incidence of hospitalised infections following rituximab among children with cSLE and to assess changes in hospital-based rituximab administration over time.

Methods: Youth ages 2-21 years with an International Classification of Diseases (ICD) code for SLE who received rituximab during admission to a Pediatric Health Information System hospital from 2009 to 2021 were included. Incidence rates for infections requiring hospitalisation over the 12 months following first rituximab administration were calculated. Rituximab use by year of hospital discharge was tabulated.

Results: We identified 1567 children with cSLE who received rituximab. 219 children were admitted with an infection within 1 year after first rituximab administration, for an incidence rate of 140 cases per 1000 patient-years. Seven children (0.44%) died during a hospitalisation with an infection in the year following rituximab administration. The most common hospitalised infections were bacterial pneumonia, sepsis and cellulitis. 12 children were hospitalised with COVID-19, none of whom died. Hospitalisations with rituximab administered decreased from 2019 to 2021.

Conclusions: In this cohort of patients with cSLE who received inpatient treatment with rituximab, we observed a 14% rate of hospitalisation with infection in the year following rituximab administration among youth with cSLE. Rituximab use declined during the COVID-19 pandemic. No fatalities with COVID-19 were observed. Given the lack of outpatient data, including doses of concomitant medications and disease activity measures, further research is needed to identify risk factors for infection following rituximab among children with cSLE.

Keywords: Biological Products; Infections; Lupus Erythematosus, Systemic; Lupus Nephritis; Therapeutics.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

Figures

Figure 1
Figure 1. Proportion of hospitalisations with rituximab administered by discharge year and length of stay (LOS).
See this image and copyright information in PMC

References

    1. Barmettler S, Ong MS, Farmer JR, et al. Association of Immunoglobulin Levels, Infectious Risk, and Mortality With Rituximab and Hypogammaglobulinemia. JAMA Netw Open. 2018;1:e184169. doi: 10.1001/jamanetworkopen.2018.4169. - DOI - PMC - PubMed
    1. Luna G, Alping P, Burman J, et al. Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies. JAMA Neurol. 2020;77:184–91. doi: 10.1001/jamaneurol.2019.3365. - DOI - PMC - PubMed
    1. Dale RC, Brilot F, Duffy LV, et al. Utility and safety of rituximab in pediatric autoimmune and inflammatory CNS disease. Neurology (ECronicon) 2014;83:142–50. doi: 10.1212/WNL.0000000000000570. - DOI - PMC - PubMed
    1. McAtee CL, Lubega J, Underbrink K, et al. Association of Rituximab Use With Adverse Events in Children, Adolescents, and Young Adults. JAMA Netw Open. 2021;4:e2036321. doi: 10.1001/jamanetworkopen.2020.36321. - DOI - PMC - PubMed
    1. Ong MS, Rothman D, Barmettler S, et al. New-onset hypogammaglobulinaemia and infectious complications associated with rituximab use in childhood-onset rheumatic diseases. Rheumatology (Oxford) 2022;61:1610–20. doi: 10.1093/rheumatology/keab626. - DOI - PubMed

LinkOut - more resources